Blosozumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Blosozumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target SOST
Identifiers
CAS Number 1132758-87-2 N
ATC code none
ChemSpider none
KEGG D10094 N
Chemical data
Formula C6462H9852N1684O2030S46
Molar mass 144.63 kg/mol
 NYesY (what is this?)  (verify)

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1]

Blosozumab was developed by Eli Lilly and Company.

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information 25 (2).